
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina has demonstrated an ability to increase revenue even as it reduces the cost of sequencing, attributed to demand elasticity, which suggests that higher sample volumes and deeper sequencing requirements can counterbalance price declines. The company aims to accelerate revenue growth to high single digits by 2027, underpinned by a strong pipeline of multiomic technologies and workflows. Additionally, Illumina maintains robust earnings per share growth projections, anticipating approximately 14% growth in 2026, despite potential headwinds in the Chinese market, indicating solid underlying financial health and future profitability.
Bears say
Illumina has lowered its 2025 guidance for non-GAAP diluted EPS to $4.50, reflecting reduced earnings expectations primarily due to challenges in the Chinese market and ongoing macroeconomic trends. The company faces significant headwinds, including a 40% decline in stock value since Q4'24, largely driven by concerns over potential operational limitations in China and increased competition within the life sciences tools sector. Additionally, the persistent demand weakness in China, which represents about 7% of sales, further complicates Illumina's revenue growth prospects and may result in its valuation continuing to trade at a discount compared to industry peers.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares